{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:07:39Z","timestamp":1791306459886,"version":"4.3.1"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2022.1097968","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T02:21:55Z","timestamp":1670552515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension"],"prefix":"10.3389","volume":"13","author":[{"given":"Imma","family":"Forzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Mone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Varzideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislovas S.","family":"Jankauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urna","family":"Kansakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Santulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvz057","article-title":"Resistant hypertension: new insights and therapeutic perspectives","volume":"6","author":"Ruilope","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106557","article-title":"Therapeutic concordance improves blood pressure control in patients with resistant hypertension","author":"Trimarco","year":"2022","journal-title":"Pharmacol Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1161\/HYPERTENSIONAHA.116.07806","article-title":"Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension","volume":"68","author":"Dudenbostel","year":"2016","journal-title":"Hypertension"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"British Hypertension society's PSG: Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"B6","first-page":"495","article-title":"Osilodrostat: First approval","volume-title":"Drugs","author":"Duggan","year":"2020"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6625-7_11","article-title":"Analysis of the aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes","volume":"1527","author":"MacKenzie","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","author":"Freeman","year":"2022","journal-title":"Hypertens Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","author":"Freeman","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1097968\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T02:21:57Z","timestamp":1670552517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1097968\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":10,"alternative-id":["10.3389\/fendo.2022.1097968"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1097968","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"article-number":"1097968"}}